Translational Lab for Biomarker Discovery
European ScreeningPort (ESP) has set up a facility for Biomarker Discovery embedded within the Centre for Molecular Neurobiology Hamburg (ZMNH) at the University Medical Center Hamburg-Eppendorf (UKE).
The ESP has established a new Translational Research and Biomarker facility which will be sited at the Centre for Molecular Neurobiology Hamburg (Zentrum für Molekulare Neurobiologie Hamburg, ZMNH), part of the University Medical Center Hamburg-Eppendorf (Universitätsklinikum Eppendorf, UKE). The aim of the facility will be to apply translational research methods to identify and validate novel molecular biomarkers, with a focus on Multiple Sclerosis. The new biomarkers will be used as a basis for the development of disease relevant bioassays and diagnostic tools in order to advance basic research as well as support the UKE's portfolio of Drug Discovery projects.
The joint Biomarker platform is part of a network of infrastructures created within the framework of the Neu2 consortium, which is funded by the German Government and a group of industry partners, including Merck Serono (http://www.neu-quadrat.de). The aim of Neu2 is to strengthen the development of innovative pharmaceuticals for Multiple Sclerosis (MS). MS is an autoimmune disease leading to a chronic inflammation of the central nervous system. It is one of the major neurological diseases with approximately 2.5 million patients world-wide.